Based on the favorable results of the oral drug ProLectin-M on COVID-19 patients [195], BioOxyTran developed a few intravenous injectable drugs around ProLectin-M (ProLectin-I, ProLectin-F, ProLectin-V, and ProLectin-A) for various viral diseases including severe COVID-19, influenza, pulmonary fibrosis, monkeypox, ebola, and ARDS—some of them are in the Investigational New Drug (IND) stage (see Table 3). This evidence concerns the gene CLEC17A and acute respiratory distress syndrome.